CLOVER BIOPHARMACEUTICALS



SCB-219M
Preliminary Phase 1 Data

December 2023

Disclaimer

This presentation contains certain forward-looking statements and information relating to us and our subsidiaries that are based on the beliefs of our management as well as assumptions made by and information currently available to our management. When used, the words "aim," "anticipate," "believe," "could," "estimate," "expect," "going forward," "intend," "may," "might," "ought to," "plan," "potential," "predict," "project," "seek," "should," "will," "would" and the negative of these words and other similar expressions, as they relate to us or our management, are intended to identify forward-looking statements.

Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. We give no assurance that these expectations and assumptions will prove to have been correct. Because forward-looking statements relate to the future, they are participant to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. We caution you therefore against placing undue reliance on any of these forward-looking statements. Any forward-looking statement made by us in this document speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. Participant to the requirements of applicable laws, rules and regulations, we undertake no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. All forward-looking statements contained in this document are qualified by reference to this cautionary statement.

SCB-219M (TPO Mimetic Bispecific-Fc)

- SCB-219M is a novel fusion protein (TPO mimetic bispecific-Fc) in Phase 1 Clinical Testing
- Initially targeted to treat Chemotherapy-Induced Thrombocytopenia (CIT)

Potential Significant Differentiation & Advantages Compared to Commercially-Available Native TPO-Based Therapy in China

- ✓ **Potent & Durable Efficacy:** SCB-219M may potentially overcome reduced efficacy observed for native TPO therapy due to anti-drug antibodies (ADA)
- ✓ **More Convenient Dosing:** SCB-219M's longer half-life may enable it to achieve a more convenient dosing regimen compared to both native TPO-based therapy and Nplate (romiplostim)
- ✓ **Blockbuster Market Potential:** Product sales for native TPO-based therapy (TPIAO) in China reached **over RMB 3 billion** in 2022
- ✓ Opportunities for near-term **value creation via development & commercial partnerships in China and globally** for SCB-219M to be evaluated

Blood Platelet Level in SD Rats



Phase 1 Clinical Trial Data Readout in Chemotherapy-Induced Thrombocytopenia (CIT) Announced in DEC-2023

CLOVER BIOPHARMACEUTICALS

Preliminary Phase 1 Data: *Efficacy*

- ✓ **Significant platelet count maintenance/recovery observed in CIT patients with a single dose of SCB-219M** (on Day 1) **following chemotherapy** (on Day 0)
- ✗ **Compared to chemotherapy-alone, where platelet counts dropped by >40% versus baseline** (in the same Phase 1 patients prior to study enrollment)



Note: Preliminary Phase 1 results in 9 CIT patients (data not final and subject to change). Chemotherapy infusion administered on Day 0 (D0), and SCB-219 administered subcutaneously on Day 1 (D1). Mean values ± Standard errors (SE) shown (where available).

CLOVER BIOPHARMACEUTICALS

Preliminary Phase 1 Data: *Efficacy*

- ✓ All CIT patients enrolled maintained platelet counts >75 x 10^9/L at 1-week following chemotherapy and a single dose of SCB-219M, with durable response through at least 3-weeks
- ✗ In comparison, following chemotherapy-alone (without SCB-219M) in the same patients prior to enrolling into the trial, all patients observed platelet counts drop to <75 x 10^9/L between one and three weeks



Note: Preliminary Phase 1 results in 9 CIT patients (data not final and subject to change). Chemotherapy infusion administered on Day 0 (D0), and SCB-219 administered subcutaneously on Day 1 (D1). Mean values ± Standard errors (SE) shown (where available). Grey lines represent individual CIT patients.

CLOVER BIOPHARMACEUTICALS

Preliminary Phase 1 Data: *Safety & Pharmacokinetics (PK)*

Pharmacokinetic (PK) Profile

- **Serum half-life of SCB-219M observed to be approximately 14 days or longer**
- **Combined with the durable efficacy observed, is potentially supportive of dosing intervals ≥2-weeks, which would enable convenient dosing synchronized with any given patient's chemotherapy regimen**
  - In contrast to current standard of care biologic treatments for CIT in China requiring daily injections (1) and globally requiring weekly injections (2)



Safety Profile

- **Favorable safety and tolerability profile for SCB-219M observed to-date**
- **No serious adverse events (SAEs)**
- **No dose-limiting toxicity (DLT)**

Phase Ib trial evaluating repeated dosing of SCB-219M in CIT and cancer therapy-induced thrombocytopenia (CTIT) patients is planned to initiate in 2024

Note: Preliminary Phase 1 results in 9 CIT patients (data not final and subject to change).
(1) TPIAO (3SBio).
(2) Nplate romiplostim (Amgen).

CLOVER BIOPHARMACEUTICALS

Thank You!